Healthcare / Drug Manufacturers - Specialty & GenericStockholm
$0.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-37.2M · quality 79.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$29M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-58.8%
↓Gross Margin
67.3%
↑Debt/Equity
0.25
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-30.3%
FCF CAGR
—
FCF margin
—
FCF / Net income
—
Latest source
Provider fallback
Margin decomposition
Último año: revenue $14.8M · net income $-22.5M · FCF —
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $14.8M | $14.8M | $26.9M | $37.1M | $43.6M |
| Net Income | $-22.5M | $-22.5M | $-60.0M | $-42.6M | $-36.9M |
| EBITDA | $-13.6M | $-13.6M | $-51.9M | $-34.0M | $-27.8M |
| EPS | -0.00 | -0.00 | -0.01 | -0.02 | -0.06 |
| Gross Margin | 67.3% | 67.3% | 56.4% | 43.9% | 53.6% |
| Operating Margin | -131.5% | -131.5% | -151.0% | -111.0% | -77.0% |
| Net Margin | -152.1% | -152.1% | -223.2% | -114.7% | -84.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.25 | 0.25 | 0.26 | 0.18 | 0.41 |
| Current Ratio | 0.49 | 0.49 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | — | — | $-38.8M | $-35.7M | $-41.2M |
| Returns | |||||
| ROE | -58.8% | -58.8% | -123.6% | -56.5% | -78.3% |
| Valuation | |||||
| P/B | 0.43 | 0.43 | 0.56 | 2.08 | 1.22 |
| Growth & Yield | |||||
| Revenue Growth | -45.0% | -45.0% | -27.6% | -14.9% | — |
| EPS Growth | 100.0% | 100.0% | 20.6% | 70.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-53.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.01 → -0.00
Residual
-53.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.